Acacia Pharma to present at the Upcoming Degroof Petercam Virtual Healthcare Conference

 Acacia Pharma to present at the Upcoming Degroof Petercam Virtual Healthcare Conference

Cambridge, UK and Indianapolis, US – 21 January 2021: Acacia Pharma Group plc (“Acacia Pharma” or the "Company”) (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or chemotherapy, announces that Mike Bolinder (CEO) and Gary Gemignani (CFO) will present a company overview to investors at Degroof Petercam’s upcoming Virtual Healthcare Conference, which will take place on 26-29 January 2021.

Presentation slides will be made available after the event through the investor section of the Company’s website, www.acaciapharma.com.   

###

Contacts

Acacia Pharma Group plc Mike Bolinder, CEO Gary Gemignani, CFO [phone] / [phone] [e-mail]	International Media Mark Swallow, Frazer Hall, David Dible Citigate Dewe Rogerson [phone] [e-mail]
US Investors LifeSci Advisors Irina Koffler [phone] [e-mail]	Media in Belgium and the Netherlands Chris Van Raemdonck [phone] [e-mail]

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy. The Company has identified important and commercially attractive unmet needs in these areas that its product portfolio aims to address.

Acacia Pharma's first product, BARHEMSYS (amisulpride injection) is available in the US for the management of postoperative nausea & vomiting (PONV).

BYFAVO (remimazolam) for injection, a very rapid onset/offset IV benzodiazepine sedative is approved in the US for use during invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. BYFAVO is in-licensed from Paion UK Limited for the US market.

APD403 (intravenous and oral amisulpride), a selective dopamine antagonist for chemotherapy induced nausea & vomiting (CINV) has successfully completed one proof-of-concept and one Phase 2 dose-ranging study in patients receiving highly emetogenic chemotherapy.

Acacia Pharma has its US headquarters in Indianapolis, IN and its R&D operations are centred in Cambridge, UK. The Company is listed on the Euronext Brussels exchange under the ISIN code GB00BYWF9Y76 and ticker symbol ACPH.

www.acaciapharma.com

Forward looking statements

This announcement includes forward-looking statements, which are based on current expectations and projections about future events. These statements may include, without limitation, any statements preceded by, followed by or including words such as "believe", "expect", "intend", "may", "plan", "will", "should", "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements may and often do differ materially from actual results. These forward-looking statements are subject to risks, uncertainties and assumptions about the Company and its subsidiaries and investments, including, among other things, the development of its business, trends in its operating industry, and future capital expenditures and acquisitions. By their nature, forward-looking statements involve risk and uncertainty because they relate to future events and circumstances. Any forward-looking statements reflect the Company's current view with respect to future events and are subject to risks relating to future events and other risks, uncertainties and assumptions relating to the Group's business, results of operations, financial position, prospects, growth or strategies and the industry in which it operates. Save as required by law or applicable regulation, the Company and its affiliates expressly disclaim any obligation or undertaking to update, review or revise any forward-looking statement contained in this announcement whether as a result of new information, future developments or otherwise. Forward-looking statements speak only as of the date they are made.